Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study
Bibliographic record
Abstract
Deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor is approved in multiple countries for the treatment of adults with moderate to severe plaque psoriasis 1,2 • Pivotal phase 3 trials, POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751) 3,4 have demonstrated that deucravacitinib was significantly more efficacious than placebo and apremilast and was well tolerated in patients with moderate to severe plaque psoriasis -Deucravacitinib has also demonstrated long-term maintenance of efficacy and a consistent safety profile through 5 years of continuous treatment 5 • The Registry of Psoriasis Health Outcomes: a Longitudinal Real-world Collaboration Study (RePhlect; NCT05744466) is designed to confirm the clinical profile of deucravacitinib by assessing its usage in a more diverse, real-world population of patients with psoriasis across North America (US and Canada), Japan, the United Kingdom, Germany, and France 6 • This study focused on the RePhlect North American cohort, a population of adults with plaque psoriasis from real-world dermatology practices in the United States and Canada, with participants enrolled from the CorEvitas Psoriasis Registry 7 Objective • This analysis compared skin clearance outcomes of deucravacitinib vs apremilast at 6 months after treatment initiation among adult patients with plaque psoriasis in the RePhlect North American region Methods Study design • RePhlect North America is a multicenter, prospective, observational, real-world study that included data from the CorEvitas Psoriasis Registry -The Registry enrolls adults from the US and Canada who have dermatologist-diagnosed plaque psoriasis -Longitudinal follow-up data were collected during routine clinical visits using CorEvitas Psoriasis Registry questionnaires -Data collected through December 2024 were included in this analysis Patient population• Patients from the CorEvitas Psoriasis Registry with plaque psoriasis who initiated treatment with deucravacitinib or apremilast and were followed prospectively (Figure 1) -Patients initiated deucravacitinib between September 9,
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.005 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.006 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".